VIR BIOTECHNOLOGY INC (VIR) Forecast, Price Target & Analyst Ratings

NASDAQ:VIRUS92764N1028

Current stock price

9.1 USD
-0.28 (-2.99%)
At close:
9.1 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VIR BIOTECHNOLOGY INC (VIR).

Forecast Snapshot

Consensus Price Target

Price Target
$16.45
+ 80.74% Upside

Next Earnings Forecast

Earnings Estimate
Release Date
May 5, 2026
Period
Q1 / 2026
EPS Estimate
-$0.29
Revenue Estimate
1.703M

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$16.45
Upside
+ 80.74%
From current price of $9.10 to mean target of $16.45, Based on 14 analyst forecasts
Low
$12.12
Median
$14.79
High
$27.30

Price Target Revisions

1 Month
-3.73%
3 Months
-6.37%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for VIR. The average price target is 16.45 USD. This implies a price increase of 80.74% is expected in the next year compared to the current price of 9.1.
The average price target has been revised downward by 6.37% in the past 3 months.

Analyst Ratings & History

Current Analyst Ratings

VIR Current Analyst RatingVIR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

VIR Historical Analyst RatingsVIR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
VIR was analyzed by 14 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VIR.
In the previous month the buy percentage consensus was at a similar level.
VIR was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-04HC Wainwright & Co.Maintains Buy -> Buy
2026-02-25BarclaysMaintains Overweight -> Overweight
2026-02-24NeedhamMaintains Buy -> Buy
2026-02-24Evercore ISI GroupMaintains Outperform -> Outperform
2026-02-24Morgan StanleyMaintains Overweight -> Overweight
2026-02-09NeedhamReiterate Buy -> Buy
2025-12-30HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-15HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-03Evercore ISI GroupInitiate Outperform
2025-08-27B of A SecuritiesUpgrade Neutral -> Buy
2025-07-11Raymond JamesInitiate Outperform
2025-05-22NeedhamReiterate Buy -> Buy
2025-05-12NeedhamMaintains Buy -> Buy
2025-04-17Goldman SachsMaintains Buy -> Buy
2025-02-28BarclaysMaintains Overweight -> Overweight
2025-02-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-27NeedhamReiterate Buy -> Buy
2025-01-31HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-13Leerink PartnersMaintains Outperform -> Outperform
2025-01-10HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-09JP MorganMaintains Neutral -> Neutral
2025-01-09Morgan StanleyUpgrade Equal-Weight -> Overweight
2024-11-20NeedhamReiterate Buy -> Buy
2024-11-20HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-04BarclaysMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 5, 2026
Period
Q1 / 2026
EPS Estimate
-$0.29
Revenue Estimate
1.703M
Revenue Q2Q
-43.83%
EPS Q2Q
67.38%
Number of Analysts
9

Next Earnings Revisions

Revenue (1 Month)
-28.46%
Revenue (3 Months)
-28.46%
EPS (1 Month)
40.87%
EPS (3 Months)
41.74%

Next Earnings Summary

VIR is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -0.29 USD and the consensus revenue estimate is 1.70M USD.
The next earnings revenue estimate has been revised downward by 28.46% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
VIR revenue by date.VIR revenue by date.
86.18M
-94.67%
74.205M
-13.90%
68.556M
-7.61%
6.653M
-90.30%
76.484M
1,049.62%
99.35M
29.90%
98.031M
-1.33%
199.54M
103.55%
490.38M
145.76%
828.88M
69.03%
1.208B
45.74%
EBITDA
YoY % growth
VIR ebitda by date.VIR ebitda by date.
-664.854M
-179.16%
-537.611M
19.14%
-467.83M
12.98%
-427.866M
8.54%
-384.099M
10.23%
-340.442M
11.37%
-286.492M
15.85%
-178.689M
37.63%
-159.216M
10.90%
42.269M
126.55%
227.47M
438.15%
EBIT
YoY % growth
VIR ebit by date.VIR ebit by date.
-684.305M
-182.14%
-552.17M
19.31%
-479.51M
13.16%
-369.521M
22.94%
-389.497M
-5.41%
-303.59M
22.06%
-370.592M
-22.07%
-303.933M
17.99%
17.928M
105.90%
303.96M
1,595.45%
589.77M
94.03%
Operating Margin
VIR operating margin by date.VIR operating margin by date.
-794.04%-744.11%-699.44%-5,554.20%-509.25%-305.58%-378.04%-152.32%3.66%36.67%48.82%
EPS
YoY % growth
VIR eps by date.VIR eps by date.
-4.59
-220.47%
-3.82
16.78%
-3.16
17.28%
-2.72
13.79%
-2.24
17.94%
-1.65
26.10%
-1.36
17.87%
-0.68
49.62%
0.08
111.82%
1.35
1,568.75%
2.58
91.39%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth
-0.29
67.38%
-0.63
21.49%
-0.63
46.13%
-0.85
-172.86%
-0.47
-65.35%
-0.47
24.42%
-0.47
24.68%
-0.47
43.88%
Revenue
Q2Q % growth
1.703M
-43.83%
2.096M
72.65%
2.267M
844.58%
2.623M
-95.91%
242.4K
-85.77%
242.4K
-88.44%
242.4K
-89.31%
242.4K
-90.76%
EBITDA
Q2Q % growth
-117.532M
14.02%
-118.994M
-5.49%
-112.492M
31.68%
-107.06M
-195.41%
-109.08M
7.19%
-112.11M
5.79%
-112.11M
0.34%
-113.12M
-5.66%
EBIT
Q2Q % growth
-87.142M
37.56%
-89.299M
24.70%
-89.964M
48.13%
-120.508M
-151.47%
-111.605M
-28.07%
-112.726M
-26.23%
-113.847M
-26.55%
-114.989M
4.58%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
13.89%
EPS Next 5 Year
12.27%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
28.19%
Revenue Next 5 Year
59.37%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
9.85%
EBIT Next 5 Year
10.48%

VIR BIOTECHNOLOGY INC / VIR Forecast FAQ

Can you provide the average price target for VIR BIOTECHNOLOGY INC stock?

14 analysts have analysed VIR and the average price target is 16.45 USD. This implies a price increase of 80.74% is expected in the next year compared to the current price of 9.1.

When does VIR BIOTECHNOLOGY INC (VIR) report earnings?

VIR BIOTECHNOLOGY INC (VIR) will report earnings on 2026-05-05.

Can you provide the consensus estimates for VIR BIOTECHNOLOGY INC next earnings?

The consensus EPS estimate for the next earnings of VIR BIOTECHNOLOGY INC (VIR) is -0.29 USD and the consensus revenue estimate is 1.70M USD.

What is the expected long term growth rate for VIR BIOTECHNOLOGY INC (VIR)?

The expected long term growth rate for VIR BIOTECHNOLOGY INC (VIR) is 28.19%.